Sotera Health (NASDAQ:SHC – Free Report) had its price target upped by JPMorgan Chase & Co. from $16.00 to $18.00 in a research report report published on Friday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock. Other analysts have also issued research reports about the company. Citigroup raised their price […]
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Sotera Health’s (SHC) Overweight Rating Reiterated at Piper Sandler | 0 | 9.05 | 10-08-2026 |
| 2 | Natera (NASDAQ:NTRA) Price Target Raised to $360.00 | 0 | 14.27 | 10-08-2026 |
| 3 | PAR Technology (NYSE:PAR) Price Target Raised to $18.00 | 0 | 14.24 | 10-08-2026 |
| 4 | Target (NYSE:TGT) Price Target Raised to $157.00 | 0 | 13.85 | 10-08-2026 |
| 5 | Replimune Group (NASDAQ:REPL) Price Target Raised to $20.00 | 0 | 13.83 | 10-08-2026 |
| 6 | Centrus Energy (NYSE:LEU) Price Target Raised to $180.00 | 0 | 13.43 | 10-08-2026 |
| 7 | Cencora (NYSE:COR) Price Target Raised to $390.00 | 0 | 11.9 | 10-08-2026 |
| 8 | Haemonetics (NYSE:HAE) Price Target Raised to $86.00 | 0 | 14.69 | 10-08-2026 |
| 9 | Banco De Chile (NYSE:BCH) Price Target Raised to $45.00 | 0 | 14.2 | 10-08-2026 |
| 10 | Odyssey Therapeutics (NASDAQ:ODTX) Price Target Raised to $29.00 | 0 | 14.24 | 10-08-2026 |